Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | PYGM | P11217 | 1/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CDA | P32320 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12212659 | 0.81 | SLC5A2 (0.42) | PYGMSLC5A2MAPTCDA | |
| SCHEMBL2495634 | 0.81 | SLC5A2 (0.42) | PYGMSLC5A2MAPTCDA | |
| SCHEMBL2497351 | 0.74 | P2RY2 (0.34) | ADORA1 | |
| SCHEMBL12212603 | 0.72 | SLC5A2 (0.46) | PYGMSLC5A2MAPTCDA | |
| SCHEMBL13488831 | 0.70 | PYGM (0.50) | PYGMSLC5A2MAPTCDATDP1 | |
| SCHEMBL12697578 | 0.70 | PYGM (0.50) | PYGMSLC5A2MAPTCDATDP1 | |
| SCHEMBL2493918 | 0.70 | PYGM (0.50) | PYGMSLC5A2MAPTCDATDP1 | |
| SCHEMBL2497342 | 0.69 | SLC29A1 (0.35) | — | |
| SCHEMBL2495653 | 0.63 | SLC5A2 (0.57) | PYGMSLC5A2MAPTCDATDP1 | |
| SCHEMBL12212604 | 0.63 | SLC5A2 (0.57) | PYGMSLC5A2MAPTCDATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1970445-B1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | RIKEN (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-8030478-B2 | Method for nucleic acid replication and novel artificial base pairs | RIKEN (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20100036111-A1 | METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS | RIKEN (JP) | 2010-02-11 | — | — | US | disclosed |
| EP-1970445-A1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | Riken (JP) | 2008-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036111-A1 | METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS | POLM, POLL, POLRMT | ADORA1 1354/4885PYGM 2344/4885SLC5A2 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.